-
1 week ago | 
insights.citeline.com | Jo Shorthouse
Merck KGaA’s Digital Biomarker Strategy For Commercial Gains In Neurology The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.
-
1 week ago | 
insights.citeline.com | Jo Shorthouse
Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision TherapiesIn Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.
-
2 weeks ago | 
insights.citeline.com | Jo Shorthouse
Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
-
2 weeks ago | 
insights.citeline.com | Jo Shorthouse
In Vivo’s 2025 Rising Leaders30 Rising Leaders Across The Life Sciences SectorThe sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
-
2 weeks ago | 
insights.citeline.com | Jo Shorthouse
In Vivo’s 2025 Rising Leaders At A Glance Top 30 leaders: see the list of industry influencers highlighted in the six edition of In Vivo's Rising Leaders series.
-
3 weeks ago | 
insights.citeline.com | Jo Shorthouse
Antag Therapeutics: Developing Peptide-Based Treatments For Obesity ManagementAntag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
-
1 month ago | 
insights.citeline.com | Jo Shorthouse
In Conversation: Sketching The Future Of Biotech Investment With Lilly VenturesLaura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape. Laura Lane and Jo Shorthouse in conversation at Bio-Europe Spring 2025 (EBD Group)
-
1 month ago | 
insights.citeline.com | Jo Shorthouse
Taking The Temperature Of UK Biotech 2025UK Life Science Leaders Talk Funding, Research And GovernmentWith British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?
-
1 month ago | 
insights.citeline.com | Jo Shorthouse
Biotech Aims For NET Gains By Targeting Neutrophil Extracellular TrapsNeutrophil Extracellular Traps are a double-edged sword in the immune system, capable of both defending against pathogens and driving inflammatory diseases. Their complex role in health and disease is being approached by innovative researchers and biotechs, who are working to harness their power while mitigating their harmful effects.
-
2 months ago | 
insights.citeline.com | Jo Shorthouse
Deals Of The Year 2024 Winners RevealedFor In Vivo's 17th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
